ABSTRACT
INTRODUCTION
The acceptability of the use of the herbal medicinal product is rising globally. The government in different countries eventually promote the use of herbal medicinal products. Herbal products are generally regarded as safe for being derived from the natural source, but this connotation needs to be supported by generating evidence. 1, 2 The Unani medicine is an ancient and traditional system of medicine being practiced since centuries having the potential for treatment of several chronic conditions; however, the need of the time is to validate these medicines as per the current regulatory requirements. 3 One of the major concerns with these medicines is underregulated quality, contamination, and adulteration of formulations available in the market 4 In addition, people often use these medicines as self-medication and also concomitantly with modern medicine. 5 Considering the above-mentioned scenario, there is an immense need for safety and efficacy data to carry out the benefits and risk analysis of Unani formulations.
Majoon-e-Kundur is a compound Unani pharmacopoeial formulation mentioned in the National Formulary of Unani Medicine, part I and other classical text of Unani system of medicine. It is recommended for Taqteer-ul-Baul (dribbling of urine), Salas-ul-Baul (Urinary incontinence), Baul Filfarash (Nocturnal enuresis), Surat-e-Inzal (Premature ejaculation) and Zof-e-Masana (Weakness of urinary bladder). 3 MK is a polyherbal Unani formulation which
. MK is one of the extensively used preparations in clinical practice, but no scientific report is available in support of safety on long-term use. Hence, the present study was designed to evaluate 180 days repeated oral toxicity study in rats.
MATERIALS AND METHODS

Experimental Animals
Sprague Dawley rats (120 ± 20 g) were used for the study. Rats were procured from National Institute of Nutrition (NIN), Hyderabad, India. Animals were kept in standard polycarbonate cages and were maintained at 22°C ± 3° C temperature and 30 to 70% of relative humidity, with a 12 hour light/12 dark cycle. 6 The experiments were conducted in accordance with the committee for the purpose of control and supervision of experiments on animals (CPCSEA) guidelines of laboratory animal care. 7 Prior approval for the study was taken from the Animals Ethics Committee of the Institute vide protocol no. CRIUM/IAEC/2015/01/P01. Animals had free excess to standard feed and water ad libitum. Rats were allowed to acclimatize to the laboratory conditions for seven days before initiating the experiment.
Drug/Formulation
Majoon-e-Kundur used in present study was formulated in the GMP certified pharmacy according to the standard procedure as mentioned in the Pharmacopoeia. 
Dose Selection
Considering the low toxicity potential of MK, a limit dose of 2,000 mg/kg bw (as per the US-FDA M3 (R2) guidance) 8 was used for the study which is approximately two times of therapeutically equivalent dose. Present study was conducted using a single dose of 2000 mg/kg body weight per day, primarily by considering the low toxicity potential (considering the long-term clinical use of MK without any serious adverse effect reported so far) as well as absence of any systemic toxicity in a subchronic (90 days) toxicity study conducted on MK in our lab (unpublished data) at two dose levels i.e., 1028 and 2000 mg/kg bw per day.
Drug Administration
Majoon-e-Kundur was administered as an a queous suspension in 0.3% CMC (<2 mL/100 gm bw). The suspension was freshly prepared every day. The control animals were administered with vehicle only. Doses were administered by oral (gavage), once daily for 180 consecutive days at a similar time each day to minimize variations.
Duration of Therapy
Duration of toxicity study for MK was 06 months (i.e., 180 days).
Experimental Method
The 180-day repeated dose oral toxicity study was carried out as according to All animals were observed for any incidence of mortality and carefully examined for the presence of morbidity twice a day during the experimental period. Further, periodical detailed clinical observations were also carried out to detect any sign associated with treatment-induced toxicity. Weekly body weights and average feed intake were also recorded. After completion of the dosing schedule, the animals were fasted overnight and anesthetized using isofluorane anesthesia system (EZ Anesthesia 1339). The blood and serum samples were collected using retro-orbital puncture for hematological and biochemical evaluation respectively.
Hemoglobin (Hb), white blood cell count (WBC), red blood cell count (RBC), platelet (PLT) and hematocrit (HCT) were analyzed using autoanalyzer (Swelab Autocounter-920EO+). Hepatic markers serum alkaline phosphatase (ALP), total bilirubin, serum aspartate transaminase (AST) and serum alanine transaminase (ALT) were analyzed. Serum creatinine and blood urea nitrogen (BUN) were analyzed as markers of renal function. Serum levels of cholesterol (TC), triglycerides (TG), total protein (TP) and albumin were analyzed using fully automatic analyzer (Erba-EM200). Serum calcium, potassium, sodium, and chloride levels were estimated using automated electrolyte analyzer (Allcare-AC9801).
All animals were sacrificed after blood collection and subjected to gross necropsy. Macroscopic examination of organs and tissues was carried out. The major internal organs/tissues were excised, trimmed and their weights were recorded. Organs/tissues samples were preserved in the neutral buffered formalin for the histopathological evaluation.
Statistical Analysis
Data were presented as a mean ± standard error of the mean (SEM) and analyzed using t-test as using GraphPad Prism (version 5). Value of p ≤ 0.05 was regarded as significant from the statistical point of view.
OBSERVATIONS AND RESULTS
Animals in both control and MK 2000 mg/kg treatment groups were subjected to clinical examination at regular time points. No abnormal behavior or clinical signs indic- ative of systemic toxicity was observed in both groups. Mortality was also not observed in both treatment groups and all animals survived throughout 180 days. Body weight gain in control and MK treated groups exhibited statistically insignificant difference throughout the study (Figs 1 and 2 ). Statistically, insignificant difference was also observed in feed intake pattern of animals of drugtreated and control groups (Figs 3 and 4) . Significant changes were also not observed in hematological parameters such as WBC, RBC count Hb, and HCT MK treated rats of either sex as compared to the control group (Table 2) . A significant increase was, however, observed in platelet count (p < 0.01 vs. control) and monocytes level (p < 0.05 vs control) of MK treated male rats.
Biochemical parameters AST, Bilirubin, ALP, total protein, albumin, globulin, A/G ratio, BUN, creatinine, triglycerides, HDL and VLDL did not show any dosedependent treatment-related changes of statistical significance MK treated animals as compared to vehicle control (Table 3) . MK treated male rats showed significantly lower serum glucose levels MK treated male rats (p < 0.001 vs. control) whereas ALT level in the same group was found to be significantly elevated (p < 0.01 vs. control). Serum ALP levels were significantly increased in MK treated female rats (p < 0.001 vs. control). MK treated groups also exhibited a significant increase in serum cholesterol (p < 0.05 vs. control for male and p < 0.01 vs. control for female), LDL levels (p < 0.05 vs. control for both sex) and HDL/LDL ratio (p < 0.05 vs. control for both sex). Further, cholesterol/HDL ratio was also significantly increased in male rats treated with MK (p < 0.05 vs. control). Serum levels of electrolytes namely sodium, potassium, chloride, and calcium in MK treated groups were comparable to control (Table 4) .
No significant change was observed in relative organ weights of brain, thymus, lungs, spleen, liver, adrenals, heart, kidney, testis, epididymis, ovaries and uterus in different treatment groups (Figs 5 and 6) .
No abnormality was observed during the gross necropsy of any animal. Changes of histological significance were observed only in the lungs and livers of animals of both control and MK treated rats. Chronic interstitial pneumonitis of different grades was observed in both control and experimental animals and hence was not considered toxicologically significant. Liver of most of the animals of both experimental and control groups were normal. The microvacuolation (MV) involving 5 to 33% of the livers observed in the females of experimental group as well as in animals of the control group and thus, may not be considered treatment-related. Other organs were found normal histologically (Figs 7A to C).
DISCUSSION
The results of the present study serve as a primer on the safety of long-term use of MK following repeated oral administration for 180 days in SD rats. No mortality was observed in any group during the study period of 180 days. Behavioral abnormality indicative of significant intoxication was also not observed in any group during the study period.
Both feed consumption and body weight gain are broad non-specific indicators of systemic toxicity. 10 Body weight gain and feed consumption dynamics of treatment groups showed normal and expected pattern in both sexes which was similar to that of the control group. This observation indicates normal and consistent growth and development pattern. Hematological and biochemical markers did not show any treatment-related alterations and were within physiological range. 7 A number of xenobiotics primarily affect the hemopoietic system making it an important indicator of toxic effects. 11 However in our study, MK treatment did not lead to any abnormal variation in the hematological profile (i.e., WBC, RBC, Hb, and HCT), indicating no effect of treatment on blood cells. While, the PLT count and monocytes level, it cannot be considered to have toxicological significance since the values remained within normal range. Hepatic toxicity is one of the common adverse effects of many clinically used agents leading to restricted use, and even wit hdrawal of drug postmarketing 12, 13 Drug-induced hepatic toxicity is characterized by alteration in ALT, AST, ALP, and bilirubin levels. 13 Elevate AST and ALT levels in some cases is caused by damaged liver parenchyma leading to their outflow into the bloodstream. [14] [15] [16] Hepatic biomarker ALT was increased in MK treated male rats, and ALP level was increased in MK treated female rats. However, the values were within the normal reference range. Thus, it may not be considered toxicologically significant. Increased levels of albumin, total and conjugated bilirubin is also a measure of overall liver function. However, all groups exhibited normal values of albumin, total bilirubin and conjugated bilirubin in the present study. Kidneys are the major organ for detoxification and drug excretion and are one of the main targets for toxic effects of drug. BUN and serum creatinine are the standard markers of kidney function in both clinical and preclinical settings. 17 In the present investigation, BUN and creatinine levels for MK treated groups were found to be within the normal range for rats. Although, values for total cholesterol were elevated significantly in MK treated rats of either sex, the values remain within physiological range and therefore, may not be considered toxicologically significant. The serum electrolyte levels of MK treated animals were also within the normal range, suggesting that MK does not affect ion homeostasis.
The organ weights evaluation is a fundamental parameter in the assessment of organ toxicity of new drugs. Society of Toxicologic Pathology states that organ/ body weight ratios should be routinely evaluated in all toxicological studies of 7 days to 1-year duration. 18 Relative organ weights (i.e., organ/body weight ratios) becomes important indicator, especially in cases where body weights are affected 18, 19 Relative organ weight of 
CONCLUSION
No toxicologically significant observation were noticed with respect to body weight, feed intake, behavioral pattern, hematology, clinical chemistry, organ weight and histopathology in MK treated group at 2000 mg/kg dose level or control animals. Therefore, MK would be considered safe based on the above observations and the reported data support the long-term clinical use of this valuable Unani formulation.
